The phase II clinical trial of CB-839 and capecitabine in patients with PIK3CA-mutated colon cancer reported here had 21.8% of patients surpassing 6 months PFS, which did not meet its prespecified objective of 25% of patients with over 6 months PFS. This evidence concerns the gene PIK3CA and malignant colon neoplasm.